Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of anlotinib
combined with sindilimab as second-line treatment for advanced esophageal squamous cell
carcinoma (ESCC). In addition, we also explored the possible mechanism of anlotinib combined
with sindilimab in order to screen out biomarkers that can predict the efficacy of the
combination therapy.